VERA Therapeutics, Inc. (NASDAQ: VERA) is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on the discovery, development and commercialization of innovative therapies for immune-mediated and gastrointestinal diseases. By integrating translational science with targeted drug design, VERA aims to deliver first-in-class or best-in-class treatments that address significant unmet medical needs.
VERA’s lead program is an oral, gut-selective small molecule designed to inhibit tissue transglutaminase-2 for the treatment of celiac disease. In parallel, the company is advancing a novel therapeutic candidate that modulates key inflammatory pathways in patients with inflammatory bowel disease (IBD). Both programs have demonstrated encouraging preclinical results and are currently progressing through early-stage clinical trials, with initial data anticipated to guide later-stage development.
Founded in 2016, VERA Therapeutics has rapidly built a diversified pipeline through a combination of in-house research and strategic collaborations. The company completed an initial public offering in 2021 and has established partnerships to support global clinical development and potential commercialization efforts. With operations and trial sites in North America and Europe, VERA is positioned to engage with regulatory authorities and clinical networks across key markets.
VERA’s leadership team brings together experienced executives from leading pharmaceutical and biotechnology firms, combining expertise in immunology, clinical development and commercial strategy. The board of directors includes recognized authorities in gastroenterology, translational medicine and drug development, providing a strong governance framework to advance VERA’s mission of bringing safe and effective therapies to patients worldwide.
AI Generated. May Contain Errors.
